

Press release

Gothenburg, Sweden, on June 18, 2026

Getinge launches Fluobeam LS, advancing fluorescence imaging for small-incision procedures

Getinge today announces the launch of Fluobeam LS, expanding its fluorescence imaging portfolio for small-incision surgery. Designed for procedures such as thyroid surgery and sentinel lymph node (SLN) detection in breast cancer, the device helps surgeons identify anatomical structures that are difficult to distinguish by providing real-time visualization to assist intraoperative decision-making.

Developed through years of clinical experience and surgeon feedback, Fluobeam LS builds on the strengths of earlier generations while addressing the access and visibility constraints of small-incision approaches. Leveraging Fluoptics' established expertise in fluorescence imaging, the device combines precision, ergonomic design and workflow efficiency to support minimally invasive surgery.

"We're committed to advancing innovation that helps surgeons achieve the best outcomes for their patients," said Stéphane Le Roy, President, Surgical Workflows at Getinge. "Fluobeam LS reflects close collaboration with surgical teams and addresses real clinical needs through a versatile platform that supports multiple indications and delivers added value for hospitals."

With a compact and lightweight design, Fluobeam LS integrates seamlessly into the operating room. Its ergonomic optical head can be positioned close to the surgical field without obstructing the view, while an integrated joystick allows intuitive control of imaging functions. High-definition imaging, combined with quantitative assessment tools, provides objective insights during critical stages of the procedure. Dedicated acquisition modes enable use across indications.

These capabilities directly support key procedural steps across the device's primary clinical applications:

- **Thyroid surgery:** Identifying and preserving parathyroid glands is essential to prevent complications such as postoperative hypocalcemia. Fluobeam LS uses fluorescence imaging to support clearer tissue differentiation, enabling surgeons to assess parathyroid perfusion with greater precision.
- **Breast cancer surgery:** Accurate SLN detection is critical but can be limited by conventional techniques. Fluobeam LS provides clear visualization of lymphatic pathways, even through small incisions, supporting accurate detection and more streamlined surgical procedures.

By contributing to improved patient care pathways, Fluobeam LS delivers both clinical and economic value for healthcare providers.

“We continue to build on our expertise in fluorescence imaging to support efficient, high-quality care delivery,” said Olivier Pacaud, Managing Director, Fluorescence Imaging at Getinge. “With its intuitive design and reliable performance, Fluobeam LS helps hospitals optimize resources, simplify surgical workflows, and strengthen coordination across clinical teams.”

Fluobeam LS was presented at the Congress of the European Society of Endocrine Surgeons in Geneva, Switzerland, in May 2026, highlighting the growing adoption of fluorescence-guided techniques in small-incision surgery. The device is CE-marked and will be commercially available in European markets.

[Find out more about Getinge’s fluorescence imaging solutions >>](#)

NB! This information is intended for an audience outside of the US.

Media contact:

Lars Mattsson, SVP Enterprise Development
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.